The South Korea AI Medical Devices and SaMD Market was valued at approximately USD 682 Million. It is projected to grow at a CAGR of around 18.5% during the forecast period of 2026–2030, reaching an estimated USD 1593.59 Million by 2030.
South Korea's AI Medical Devices and SaMD Market refers to the software-based and AI-powered medical devices that are used to assist in diagnosis, clinical decision-making, disease diagnosis, patient monitoring, and workflow optimization in the healthcare industry. Market segments include regulated medical software and intelligent medical devices utilized in the healthcare environment but excludes any non-medical consumer health applications or any general-purpose administrative software or larger healthcare IT platforms that do not perform regulated clinical functions. With the drive for efficiency and accuracy in healthcare, AI-driven medical technologies are making their mark on the daily delivery of care.
The market has grown from a technology adoption to a commercialization and integration challenge. The focus on regulatory clearances has changed. Regulatory clearance is no longer the only measure of market success. Nowadays, clinical validation, interoperability with hospital systems, cybersecurity readiness, and the ability to prove value in the real healthcare environment are gaining more importance. Meanwhile, the growth of data infrastructure and health data initiatives is driving increased interest in artificial intelligence-driven solutions in various clinical disciplines.
The market offers an interesting mix of innovation opportunities and implementation realities for decision-makers. The adoption of pathways, procurement priorities, and changing clinical needs, combined with reimbursement considerations, is becoming increasingly important to success. Healthcare organizations that match the functionality of their products with the demands of providers and workflows will be best suited for achieving sustainable growth as AI evolves from experimentation in the pilot phase to broader use in clinical practice throughout South Korea's healthcare landscape.
Key Market Insights
Research Methodology
Scope & Definitions
Evidence Collection (Primary + Secondary)
Triangulation & Validation
Presentation & Auditability
South Korea AI Medical Devices and SaMD Market Drivers
Hospitals are focused on intelligent workflow automation in clinical operations.
South Korea's healthcare market is driving accelerated investment in intelligent automation to handle the multiple levels of complexity and help boost clinical efficiency. Medical technologies powered by artificial intelligence are becoming more commonplace and are being integrated into diagnostic, monitoring, and decision support workflows, minimising administrative workload and enabling quicker clinical decisions. This trend towards modernization is driving a wider rollout of state-of-the-art software-based medical solutions throughout the country.
The need for scalable solutions is growing due to digital healthcare transformation.
South Korea is undergoing an ongoing digital transformation of the healthcare sector, which presents a promising opportunity to South Korea's medical devices and software-based clinical technologies. Healthcare organizations are looking for platforms that can be scaled up and are interoperable with current digital infrastructure yet enable information-driven care delivery. This trend is driving the growing demand for advanced solutions that deliver greater productivity, interoperability, and clinical decision-making.
The increasing emphasis on predictive care is driving technology uptake.
Predictive and proactive care models are emerging in healthcare, focusing on proactive intervention and effective resource use at an early stage. The transition is being aided by AI-powered medical technologies as they help doctors recognize patterns, prioritize cases, and optimize processes in patient management. As healthcare modernization advances, predictive capabilities are becoming a key factor influencing technology procurement decisions.
South Korea AI Medical Devices and SaMD Market Restraints
While the market shows signs of innovation, challenges remain due to fragmented clinical integration, stringent evidence generation timelines, physician resistance to algorithm transparency, and shifting cybersecurity expectations. Interoperability issues, commercialization uncertainty, and budget limitations in smaller healthcare facilities all add up to the difficulties they face when adopting. Scalable deployment in care settings is further complicated by interoperability challenges, uncertain commercialization timelines, and budget constraints in smaller health care facilities.
South Korea AI Medical Devices and SaMD Market Opportunities
The South Korean AI medical devices and SaMD market presents opportunities in terms of the growing digital transformation in hospitals, an increasing demand for better workflow automation, increasing adoption of predictive patient management tools, better integration of AI with specialty care pathways, and increasing collaboration between healthcare and technology companies to foster faster clinical implementation at a national level, with the potential for scaled implementation.
Healthcare providers identify diagnostic, workflow, or monitoring gaps.
Developers create AI medical devices or SaMD platforms targeting specific specialties.
Products undergo evaluation and approval processes.
Evidence is generated through clinical testing and performance assessment.
Developers pursue evaluation pathways that may influence payer acceptance.
Hospitals assess clinical value, workflow impact, and implementation requirements.
Organizations choose cloud-based, hybrid, or on-premise environments.
Solutions are integrated into physician workflows and healthcare systems.
Performance, safety, and operational benefits are continuously monitored.
Successful products expand across specialties including radiology, cardiology, oncology, neurology, ophthalmology, and pathology.
Why this market matters now
The market has entered a new phase. Earlier growth discussions focused heavily on regulatory approvals and technological capability. Today, buyers face a different challenge.
The critical question is whether approved AI solutions can achieve sustainable clinical adoption.
Healthcare organizations face pressure to improve efficiency while maintaining care quality. Technology vendors must prove measurable value. Investors need visibility into commercialization timelines rather than approval milestones alone.
At the same time, cybersecurity expectations, healthcare digitization initiatives, reimbursement considerations, and budget scrutiny are increasing. As a result, decision-makers require deeper analysis of adoption pathways, not just product availability.
What matters most when evaluating claims in this market
|
Claim type |
What good proof looks like |
What often goes wrong |
|
Clinical accuracy |
Independent validation and real-world outcomes |
Reliance on limited testing environments |
|
Adoption readiness |
Workflow integration evidence |
Assuming approval equals adoption |
|
Reimbursement potential |
Clear pathway assessment |
Overestimating payer acceptance |
|
Market size claims |
Transparent methodology |
Double counting overlapping categories |
|
Competitive advantage |
Measurable differentiation |
Generic AI positioning |
|
Scalability |
Multi-site deployment evidence |
Success based on isolated pilots |
The decision lens
1. Define Market Boundary
Confirm whether analysis focuses on AI medical devices, SaMD, or broader healthcare AI.
2. Verify Regulatory Position
Assess approval status, maintenance obligations, and future compliance exposure.
3. Evaluate Adoption Evidence
Compare clinical utilization data against theoretical performance claims.
4. Assess Reimbursement Path
Review how reimbursement dynamics may affect commercialization timelines.
5. Test Integration Risk
Analyze compatibility with hospital systems and operational workflows.
6. Compare Deployment Models
Evaluate cloud, hybrid, and on-premise trade-offs for security and scalability.
7. Stress-Test Growth Assumptions
Examine whether forecasts depend on realistic adoption and funding conditions.
The contrarian view
Many market assessments overstate opportunity by treating regulatory approval as the primary commercialization milestone.
Another common mistake is combining healthcare AI software, hospital IT systems, and AI medical devices into a single market estimate. This creates artificial inflation and weak comparability.
Buyers should also be cautious about using pilot programs as indicators of long-term adoption. A successful pilot does not automatically translate into enterprise-wide deployment.
Finally, reimbursement assumptions frequently introduce hidden optimism. Commercial adoption often depends on economic value demonstration, not technical capability alone.
Practical implications by stakeholder
AI Medical Device Developers
Hospitals and Health Systems
Investors and Financial Institutions
Payers and Reimbursement Stakeholders
Research Institutions
Distributors and Commercial Partners
SOUTH KOREA AI MEDICAL DEVICES AND SAMD MARKET REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2025 - 2030 |
|
Base Year |
2025 |
|
Forecast Period |
2026 - 2030 |
|
CAGR |
18.5% |
|
Segments Covered |
By Product Type, Clinical Speciality , Deployment Model , Regulatory , End User , and Region |
|
Various Analyses Covered |
Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
South korea |
|
Key Companies Profiled |
Lunit Inc., VUNO Inc., JLK Inc., Coreline Soft Co., Ltd., Samsung Medison Co., Ltd., Deep Bio Inc., Neurophet Inc., Kakao Healthcare Corporation, MEDICAL IP Co., Ltd., Mediwhale Inc., SK Telecom Co., Ltd., Heuron Co., Ltd., SEERS Technology Inc., Siemens Healthineers Korea, and GE HealthCare Korea. |
South Korea AI Medical Devices and SaMD Market Segmentation
AI medical imaging software was the largest market shareholder in 2025, with a share of 34.8%. Revenue concentration continued to support providers nationwide as strong deployment accelerated in radiology departments and imaging workloads increased, while the need for quicker diagnostic interpretation continued to drive up demand.
AI monitoring & predictive analytics software is expected to grow at a 22.8% CAGR till 2030. Proactive care, risk forecasting, and patient monitoring boost uptake across healthcare settings, particularly as these become a growing focus.
In 2025, radiology was the largest revenue contributor, with 36.5% of the revenues. The infrastructure in place, the broad use of imaging, and clinical acceptance facilitated continued leadership and helped to bring more AI-powered diagnostics into the workflow.
Pathology is poised for the highest growth at a rate of 24.1% from 2016 to 2030. The momentum of investing in digital pathology keeps rising as its adoption expands and the demand for automated tissue analysis grows.
The Seoul metropolitan area was the largest regional market, accounting for 47% of the market share. Its key strengths as the main commercialization center in the country are further bolstered by its sophisticated healthcare infrastructure, top-tier academic hospitals, digital capabilities, and innovation ecosystems.
Gyeonggi Province is expected to account for 23% of the market activity, more than any region will. Increased funding of health care, development of technology clusters and growing adoption of AI-powered medical solutions are bolstering the adoption of AI in medical environments
Latest Market News
According to the Ministry of Food and Drug Safety of South Korea, 157 AI-based software medical devices received approval in 2025, compared to 108 such approvals in 2024.
Jan 22, 2026: South Korea passed its AI Basic Act, which will place regulations on high-risk AI systems such as medical AI systems.
On November 27, 2025, Deepnoid announced that their M4CXR solution is the first generative AI medical device that has been approved as an innovative medical device by MFDS.
Lunit and Agilent Technologies inked an agreement to create companion diagnostics for precision medicine with the help of AI.
On September 22, 2025, Philips Korea introduced MR SmartSpeed Precise, which incorporates two AI-engine architectures for MRI workflows.
Jul 31, 2025: Deepnoid won the contract for the specialized medical KRW 11.6 billion project with generative AI led by the national biohealth R&D project.
Coreline Soft has signed a partnership agreement with Siemens Healthineers Korea to promote medical imaging AI technology.
On 23rd April 2025, the Deepnoid and the College of Engineering, Yonsei University, signed a joint research contract on medical imaging and AI.
Key Players
Questions buyers ask before purchasing this report
How large is the commercial opportunity beyond regulatory approvals?
The report focuses on the transition from approval to revenue generation. It examines how products move through adoption, procurement, reimbursement, and deployment stages. This provides a more realistic view of market opportunity than approval counts alone.
Why is reimbursement analysis important in this market?
Reimbursement can significantly influence adoption speed. Even technically strong products may face commercialization challenges if reimbursement pathways remain unclear. Understanding these dynamics helps reduce investment uncertainty.
Does the report separate AI medical devices from broader healthcare AI?
Yes. Proper market boundaries are critical. The analysis focuses specifically on AI medical devices and SaMD solutions to avoid market inflation and overlapping revenue estimates.
Which clinical specialties create the strongest adoption opportunities?
Different specialties face different adoption conditions. The report evaluates demand patterns across radiology, cardiology, oncology, neurology, ophthalmology, pathology, and other clinical areas.
How does deployment model affect market potential?
Deployment decisions influence scalability, compliance requirements, implementation costs, and operational flexibility. The report assesses cloud-based, hybrid, and on-premise approaches within South Korea's healthcare environment.
What risks should investors monitor most closely?
Investors should assess adoption timelines, reimbursement uncertainty, workflow integration challenges, cybersecurity requirements, and evidence-generation expectations. These factors often determine commercialization success.
How can hospitals use this report?
Hospitals can benchmark technology adoption trends, assess deployment considerations, compare specialty demand patterns, and identify factors influencing procurement decisions.
What makes market forecasts in this sector difficult?
Forecasting requires balancing regulatory progress, reimbursement developments, clinical adoption rates, procurement cycles, and technology evolution. The report examines how these variables interact rather than relying on simple growth assumptions.
The South Korea AI Medical Devices and SaMD Market was valued at approximately USD 682 Million. It is projected to grow at a CAGR of around 18.5% during the forecast period of 2026–2030, reaching an estimated USD 1593.59 Million by 2030.
Ans. The major drivers of the South Korea AI Medical Devices and SaMD Market include the increasing adoption of intelligent workflow automation across healthcare institutions, growing digital transformation initiatives within the healthcare sector, and rising demand for predictive and proactive care models. Healthcare providers are increasingly deploying AI-powered medical technologies to enhance diagnostic accuracy, improve clinical decision-making, streamline operational workflows, and optimize resource utilization. Additionally, expanding healthcare digitization, increasing demand for interoperable solutions, and the need to address workforce constraints while improving care delivery efficiency continue to support market growth across South Korea.
Ans. AI Medical Imaging Software, AI Clinical Decision Support Software, AI Diagnostic & Screening Software, AI Monitoring & Predictive Analytics Software, AI-Enabled Medical Devices, and Others are the segments under the South Korea AI Medical Devices and SaMD Market by Product Type. Radiology, Cardiology, Oncology, Neurology, Ophthalmology, Pathology, and Others are the segments by Clinical Specialty. Cloud-Based, On-Premise, and Hybrid Deployment are the segments by Deployment Model. Tertiary & General Hospitals, Specialty Hospitals, Diagnostic Imaging Centers, Clinics & Physician Practices, Academic & Research Institutions, and Others are the segments by End User. AI-Based Diagnostic SaMD, AI-Based Detection & Triage SaMD, AI-Based Monitoring SaMD, AI-Enabled Medical Devices, and Others are the segments by Regulatory Classification. Seoul Metropolitan Area, Gyeonggi Province, and Remaining South Korea Regions are the regional segments under the South Korea AI Medical Devices and SaMD Market.
The Seoul Metropolitan Area is the most dominant region in the South Korea AI Medical Devices and SaMD Market, supported by its concentration of advanced healthcare infrastructure, leading academic medical centers, strong digital health ecosystems, and extensive commercialization activities for AI-enabled healthcare technologies. Gyeonggi Province is expected to be the fastest-growing region during the forecast period of 2026–2030, driven by increasing healthcare technology investments, expanding innovation clusters, and growing adoption of AI-powered medical solutions. The remaining regions across South Korea continue to witness steady growth due to ongoing healthcare modernization efforts and broader deployment of AI-based clinical technologies.
The key players in the South Korea AI Medical Devices and SaMD Market include Lunit Inc., VUNO Inc., JLK Inc., Coreline Soft Co., Ltd., Samsung Medison Co., Ltd., Deep Bio Inc., Neurophet Inc., Kakao Healthcare Corporation, MEDICAL IP Co., Ltd., Mediwhale Inc., SK Telecom Co., Ltd., Heuron Co., Ltd., SEERS Technology Inc., Siemens Healthineers Korea, and GE HealthCare Korea.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
